Previous 10 | Next 10 |
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today anno...
2024-02-27 09:06:36 ET DENVER, Colo., Feb 27, 2024 ( 247marketnews.com )- The following companies are mentioned; Codexis (NASDAQ: CDXS ), Kraig Biocraft Laboratories (OTCQB: KBLB ), Janux Therapeutics (NASDAQ: JANX ), TransMedics Group (NASDAQ: TMDX ), and Viking Therape...
Emerging JANX007 data illustrate a potential best-in-class profile: promising efficacy with favorable safety profile in heavily pretreated subjects with late-stage mCRPC 83% (5/6) of subjects achieved PSA 50 declines with first step dose ≥ 0.2mg 56% (10/18) of subjects ...
A look at the top 10 most actives in the United States Greenbrook TMS Inc. (GBNH) rose 64.9% to $0.32 on volume of 109,974,769 shares PROSHARES TRUST (SQQQ) rose 3.7% to $12.36 on volume of 106,443,308 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 4.7% to $4.825 on volume...
2024-02-21 12:27:34 ET More on Mid-day movers & stocks. Janux Therapeutics: Precision Immunotherapy, But Overpriced For Such An Early Stage Greenbrook TMS secures $1.5M in debt financing Compass Pathways and Greenbrook TMS enter into three-year research collabora...
The virtual event will take place on Monday, February 26th, 2024, at 4:30PM ET Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activat...
2024-02-10 14:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today an...
2023-12-15 15:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-12-13 07:12:15 ET Summary Janux Therapeutics is a biotech focused on developing novel immunotherapeutic approaches for cancer patients. Their lead candidate, JANX007, is a tumor-activated T-cell engager that targets PSMA in prostate cancer. Janux also has two other molecu...
News, Short Squeeze, Breakout and More Instantly...
Janux Therapeutics Inc. Company Name:
JANX Stock Symbol:
NASDAQ Market:
Janux Therapeutics Inc. Website:
The appointment of Eric Dobmeier and Natasha Hernday to the Board brings extensive operational and business development experience to support corporate and pipeline strategy Janux also announced the resignation of Jay Lichter, Ph.D., from the Board, and the appointment of current Board me...
2024-06-12 18:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...